Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek(R) 2025
SHANGHAI and WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) — Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity, today announced an oral presentation at ObesityWeek(R) 2025, […]